Drug Trial Radar · NCT01839604
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
May 2013
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Ionis Pharmaceuticals, Inc.
- First posted
- Apr 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.
Conditions
- Advanced Adult Hepatocellular Carcinoma
- Hepatocellular Carcinoma Metastatic
Interventions
AZD9150Drug
Intravenous infusion over 3 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities During Cycle 1Time frame: DLT assessment window - Cycle 1 (22 days)
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Hong Kong, Hong Kong
Research Site
Chūōku, Japan
Research Site
Kashiwa-shi, Japan
Research Site
Matsuyama, Japan
Research Site
Seoul, South Korea
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.